Ligand Pharmaceuticals Inc (NASDAQ: LGND) has reported a loss for its second fiscal quarter (ending June 30) of $-2.88 versus $0.13 for the same period a year ago — a decline of -2315%. This result fell short of the consensus estimate of $1.06 by $-3.94. For the latest four quarters through June 30, E.P.S. were $2.36 versus $2.38 for the same period a year ago — a decline of -1%.
Recent Price Action
On 8/6/24, Ligand Pharmaceuticals Inc (NASDAQ: LGND) stock rose modestly by 0.9%, closing at $99.04. Trading volume in this advance was normal. The stock has declined -8.9% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, LGND is expected to continue to be an important Value Builder.
Ligand Pharmaceuticals has a current Value Trend Rating of C (High Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Ligand Pharmaceuticals has a poor Appreciation Score of 29 but a very high Power Rating of 92, triggering the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment